# A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct03934567/  
OnCo record `nct03934567` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abexinostat in non-Hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03934567 by Xynomic Pharmaceuticals, Inc., with 87 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2025-01-29. Interventions recorded: Abexinostat.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03934567
- Phase: 2
- Setting: An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)
- Sponsor: Xynomic Pharmaceuticals, Inc.
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT03934567: https://clinicaltrials.gov/study/NCT03934567

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct03934567.json